Progesterone-related diabetes mellitus (PRDM) in dogs is known for its particular potential for diabetes remission. This narrative review aims to provide relevant detailed information on (1) the canine estrus cycle and its impact on canine diabetes mellitus (CDM) etiology and management, (2) the role of pyometra as a further cause of insulin resistance, and (3) useful individual therapeutic and preventive strategies. PRDM is recognized due to diestrus, exogenous progestogen exposure, pregnancy, and P4-production ovarian dysfunction. Pyometra represents additional inflammatory and septic negative influence on insulin sensitivity, and its diagnosis associated with CDM is therapeutically challenging. The estrus cycle’s hormone fluctuations seem to modulate peripheric insulin sensibility by influencing insulin receptor (IR) affinity and its binding capacity, as well as modulating tyrosine kinase activity. Pyometra was shown to negatively influence IR compensatory mechanisms to insulin resistance causing glucose intolerance. Spaying and pregnancy termination may cause diabetes remission in PRDM cases in a median time of 10 days (1–51). Pharmacological annulment of progesterone effects may benefit patients unable to undergo surgery; however, remission chances are virtually null. The ALIVE (Agreeing Language in Veterinary Endocrinology) project proposed new criteria for CDM diagnoses and subclinical diabetes recognition. These new concepts may increase the frequency of a PRDM diagnosis and, even more, its relevance. Spaying represents a preventive measure against pyometra and PRDM that should be individually assessed in light of its recognized benefits and harms.
Portable blood glucose meters (PBGMs) are essential for detecting glycemic disorders. In Brazil, veterinary devices are scarce, and human devices are used as an alternative. This study evaluated the accuracy of three human glucometers: Accu-Chek Guide® (ACG) and Accu-Chek Guide Me® (ACGM) (Roche), and EcoCheck® (EC) (Eco Diagnóstica). A total of 419 glycemic samples were collected and compared to the glucose oxidase method (GOM), considered the gold standard. Despite a strong positive correlation compared to the GOM (ACG r = 0.96; ACGM r = 0.9; EC r = 0.89; P <0.0001), when evaluated by the criteria defined by ISO15197:2013 for analytical precision, no PG obtained 99% of the readings within the range of +/- 15 for glucose levels 100mg/dL (ACG = 57.9%, ACGM = 47.9%, and EC = 28.4%). ACG was the only PG that fully met the clinical precision criteria according to ISO15197:2013, with 100% of its measurements in zones A+B of the error grid. Despite analytical inaccuracy, ACG PBGM proved to be the best among the devices tested in this study for use in dogs with whole blood samples, not generating any negative impact on animal health.
Correlations among estrus cycle, pyometra, and canine diabetes mellitus (CDM) have been described since the late 1950s, and substantial progress in understanding mechanisms beyond was achieved nowadays. Progesterone-related diabetes mellitus (PRDM) in dogs is known for its particular potential for diabetes remission. Thus, a deep understanding of the physiopathological aspects involved is crucial to postulate treatment guidelines to improve the PRDM remission rate, as well as to inform preventive measures. This narrative review aims to provide relevant detailed information on 1) canine estrus cycle and its impact on CDM etiology and management, 2) the role of pyometra as a further cause of insulin resistance, and 3) useful individual therapeutic and preventive strategies. Pharmacological annulment of progesterone effects, as well as inflammatory and progesterone-related conditions resolution in association with adequate exogenous insulin therapy, and residual beta cell function, are key aspects to achieve remission, or at least to improve diabetic clinical control. In this way, spaying should be considered mandatory in most PRDM cases. Preventive measures against CDM can include spaying recommendations; however, individual-based recommendations should be considered since castration may be associated with some long-term health issues.
Pregnant ewes are susceptible to hypoglycemia and ketosis; therefore, monitoring glycemic status is extremely important. Portable blood glucose meters (PBGM) can assist in quickly and conveniently identifying glycemic disturbances in this species, provided that they meet criteria demonstrating their analytical accuracy. This study evaluated the performance of a human PBGM (Accu-Chek Performa®, Roche Diagnostics, Basel, Switzerland), for glycemic evaluation of 34 pregnant ewes at 90 and 120 pregnancy days in comparison with glycemia determination by a reference method (RM). The device showed a high positive correlation (r = 0.71, 95%CI = 0.57 – 0.82, P < 0.0001) with the RM; however, 96.6% of the PBGM results (58.5 ± 9.82 mg/dL) were higher (P < 0.0001) than those obtained in the laboratory (48.6 ± 9.31 mg/dL). The PBGM tested was considered analytically inaccurate according to ISO 15197:2013 which states when glucose is <100 mg/dL, 95% of its measurements should not differ by more than 15 mg/dL from the RM value, while 1/3 of the PBGM results read up this limit. Hypoglycemia (< 50 mg/dL) was documented in 60.29% of samples measured by the RM, but only 17.64% read below 50 mg/dL in the PBGM. Due to these limitations, Accu-Check Performa® results should be interpreted cautiously in pregnant sheep suspected of hypoglycemia.
Pregnant ewes are susceptible to hypoglycemia and ketosis; therefore, monitoring glycemic status is extremely important. Portable blood glucose meters (PBGMs) can assist in quickly and conveniently identifying glycemic disturbances in this species, provided that they meet the criteria of analytical accuracy. This study evaluated the performance of a human PBGM (Accu-Chek Performa®, Roche Diagnostics, Basel, Switzerland) in the glycemic evaluation of 34 pregnant ewes at days 90 and 120 of pregnancy in comparison with the results of glycemia determination by a reference method (RM). The device showed a high positive correlation (r = 0.71, 95%CI = 0.57–0.82, p < 0.0001) with the RM; however, 96.6% of the PBGM results (58.5 ± 9.82 mg/dL) were higher (p < 0.0001) than those obtained in the laboratory (48.6 ± 9.31 mg/dL). The PBGM tested was considered analytically inaccurate according to ISO 15197:2013, which states that when glucose levels are below 100 mg/dL, 95% of the measurements should deviate by no more than 15 mg/dL from the RM value, and 1/3 of the PBGM results were above this limit. Hypoglycemia (<50 mg/dL) was documented in 60.29% of samples tested on with the RM, but only 17.64% of results were below 50 mg/dL using the PBGM. Due to these limitations, Accu-Check Performa® results should be interpreted cautiously in pregnant sheep suspected of hypoglycemia.
6 November 2026 in Veterinary Research Communications
This study evaluated adjunctive dapagliflozin therapy in insulin-treated diabetic dogs to assess short- and long-term glycemic, clinical, and laboratory outcomes in dogs with naturally occurring diabetes mellitus. Six diabetic dogs received a compounded liquid oral dapagliflozin (CLODapa) formulation (0.088 ± 0.013 mg/kg once daily) in addition to ongoing insulin therapy for 100 days. We monitored continuous glucose monitoring (CGM) before and after treatment initiation, and serially assessed clinical, biochemical, and urinary parameters. Short-term dapagliflozin administration significantly reduced mean interstitial glucose, glucose nadir and peak values, and increased time within the target glucose range (60–250 mg/dL), while decreasing time above range. Glycemic variability increased, although time spent < 60 mg/dL and clinical hypoglycemia did not increase; however, CLODapa’s initial dosage was reduced in four dogs due to concerns about hypoglycemia, increased in one, and left unchanged in another. Long-term treatment was associated with reductions in fructosamine, systolic blood pressure, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and cholesterol concentrations. No evidence of diabetic ketoacidosis, urinary tract infection, electrolyte imbalance, or acid–base disturbance was detected. Unintentional weight loss was documented in three patients and required a ~ 25% increase in food intake. Adjunctive dapagliflozin showed promise in improving glycemic control in diabetic dogs despite posing a risk of hypoglycemia, supporting further investigation of SGLT2 inhibition in canine diabetology.